ImmunityBio, Inc. (IBRX)
NASDAQ$2.87
Market Cap
$2.45B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
628 of 924
Rank in Industry
359 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
IBRX Insider Trading Activity
IBRX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as …
Insider Activity of ImmunityBio, Inc.
Over the last 12 months, insiders at ImmunityBio, Inc. have bought $0 and sold $0 worth of ImmunityBio, Inc. stock.
On average, over the past 5 years, insiders at ImmunityBio, Inc. have bought $15.1M and sold $8.41M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 71,915 shares for transaction amount of $198,023 was made by BLASZYK MICHAEL D (director) on 2023‑06‑05.
List of Insider Buy and Sell Transactions, ImmunityBio, Inc.
| 2023-06-05 | BLASZYK MICHAEL D | director | 71,915 0.0166% | $2.75 | $198,023 | +30.82% | ||
| 2023-06-02 | Brennan John Owen | director | 25,000 0.006% | $2.83 | $70,700 | +31.77% | ||
| 2023-06-02 | Brennan John Owen | director | 15,000 0.0035% | $2.78 | $41,700 | +31.77% | ||
| 2023-06-01 | Clark Wesley | director | 7,000 0.0016% | $2.91 | $20,370 | +24.15% | ||
| 2021-10-08 | Adcock Richard | CEO & President | 1,930 0.0005% | $8.81 | $16,995 | -38.25% | ||
| 2021-08-23 | Sale | Cohen Cheryl | director | 14,801 0.0035% | $10.12 | $149,795 | -45.86% | |
| 2021-08-20 | Sale | Cohen Cheryl | director | 9,976 0.0025% | $10.00 | $99,808 | -41.00% | |
| 2021-08-18 | Sale | Cohen Cheryl | director | 2,133 0.0006% | $10.03 | $21,389 | -36.74% | |
| 2021-08-17 | Sale | Cohen Cheryl | director | 43,398 0.0112% | $10.12 | $439,361 | -41.04% | |
| 2021-05-25 | Sale | Simon Barry J. | director | 88,787 0.0237% | $16.18 | $1.44M | -54.64% | |
| 2021-05-24 | Sale | Simon Barry J. | director | 21,223 0.0056% | $16.02 | $340,071 | -54.46% | |
| 2021-05-21 | Sale | Simon Barry J. | director | 14,990 0.0039% | $16.09 | $241,164 | -53.43% | |
| 2021-02-05 | Sale | Simon Barry J. | See remarks | 22,100 0.0056% | $23.09 | $510,267 | -52.76% | |
| 2021-02-02 | Sale | Simon Barry J. | See remarks | 82,070 0.0212% | $20.65 | $1.69M | -46.10% | |
| 2021-01-28 | Sale | Simon Barry J. | See remarks | 11,304 0.0033% | $20.53 | $232,121 | -39.34% | |
| 2021-01-27 | Sale | Simon Barry J. | See remarks | 36,626 0.01% | $20.61 | $754,946 | -42.76% | |
| 2021-01-12 | Sale | Nelson Sonja | Chief Financial Officer | 16,364 0.004% | $15.00 | $245,460 | -26.52% | |
| 2021-01-04 | Sale | Nelson Sonja | Chief Financial Officer | 39,271 0.0102% | $13.62 | $534,938 | -6.48% | |
| 2020-12-22 | Sale | Simon Barry J. | See remarks | 130,000 0.1231% | $18.05 | $2.35M | -22.23% | |
| 2020-12-10 | Sale | Thomas John C | director | 42,592 0.0385% | $10.83 | $461,122 | +25.09% |
Total: 80
Insider Historical Profitability
<0.0001%
| SOON-SHIONG PATRICK | Chairman and CEO | 23750750 2.7829% | $68.16M | 2 | 0 | <0.0001% |
| BLASZYK MICHAEL D | director | 71915 0.0084% | $206,396.05 | 1 | 0 | +30.82% |
| Brennan John Owen | director | 15000 0.0018% | $43,050.00 | 2 | 0 | +31.77% |
| Clark Wesley | director | 8000 0.0009% | $22,960.00 | 1 | 0 | +24.15% |
| Wilson Angela | Chief Financial Officer | 3265 0.0004% | $9,370.55 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$193,151,375 | 134 | 8.18% | $2.73B | |
$11,588,217 | 69 | 42.07% | $2.55B | |
$1,376,668 | 53 | 18.46% | $2.27B | |
$224,267,561 | 40 | 26.78% | $2.17B | |
$1,275,975,557 | 32 | 19.44% | $2.92B |
IBRX Institutional Investors: Active Positions
| Increased Positions | 118 | +66.67% | 22M | +31.07% |
| Decreased Positions | 66 | -37.29% | 8M | -11.39% |
| New Positions | 44 | New | 10M | New |
| Sold Out Positions | 24 | Sold Out | 2M | Sold Out |
| Total Postitions | 229 | +29.38% | 84M | +19.68% |
IBRX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $57,010.00 | 2.37% | 17.33M | +425,713 | +2.52% | 2024-12-31 |
| Blackrock, Inc. | $44,694.00 | 1.86% | 13.58M | +2M | +14.57% | 2024-12-31 |
| State Street Corp | $32,193.00 | 1.34% | 9.79M | +1M | +13.06% | 2024-12-31 |
| Morgan Stanley | $13,179.00 | 0.55% | 4.01M | +2M | +78.28% | 2024-12-31 |
| Geode Capital Management, Llc | $12,637.00 | 0.53% | 3.84M | -5,757 | -0.15% | 2024-12-31 |
| Woodline Partners Lp | $11,326.00 | 0.47% | 3.44M | +3M | +682.7% | 2024-12-31 |
| Cormorant Asset Management, Lp | $9,870.00 | 0.41% | 3M | +3M | New | 2024-12-31 |
| Tang Capital Management Llc | $9,259.00 | 0.39% | 2.81M | +3M | New | 2024-12-31 |
| Ubs Group Ag | $5,223.00 | 0.22% | 1.59M | +1M | +290.64% | 2024-12-31 |
| Credit Suisse Ag/ | $5,096.00 | 0.21% | 1.55M | +18,918 | +1.24% | 2024-03-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.